Novanta posts Q3 2026 results, beats revenue and EPS estimates, but trims full‑year EPS outlook
Novanta Inc. reported third‑quarter 2026 GAAP revenue of $305 million, a 23% year‑over‑year increase, and adjusted diluted EPS of $1.05, beating consensus by $0.11. GAAP diluted EPS was $0.05. The company also disclosed that the Riverpoint Medical acquisition contributed $32.9 million to revenue. For the fourth quarter it guided GAAP revenue of $306 million‑$312 million and full‑year 2026 revenue of $1.135 billion‑$1.14 billion, while lowering its adjusted full‑year EPS target to $3.69.
Why it matters
The earnings beat may support short‑term price support, but the reduced full‑year adjusted EPS guidance signals slower profit growth than previously expected. Investors will need to reassess valuation models that relied on the prior EPS outlook.
Key facts
- 1GAAP revenue for Q3 2026 was $305 million, up 23% YoY. standard-freeholder.com
- 2Adjusted diluted EPS for Q3 2026 was $1.05, up 21% YoY. standard-freeholder.com
- 3GAAP diluted EPS for Q3 2026 was $0.05. standard-freeholder.com
- 4The Riverpoint Medical acquisition added $32.9 million to Q3 revenue. tradingview.com
- 5Full‑year 2026 GAAP revenue guidance is $1.135 billion‑$1.14 billion. standard-freeholder.com
- 6Q4 2026 GAAP revenue guidance is $306 million‑$312 million. standard-freeholder.com
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.